Preferred Label : pemigatinib;

MeSH synonym : 2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-;

MeSH hyponym : INCB-054828;

UNII : Y6BX7BL23K;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-atu-rtu/pemigatinib-4-5-mg-9-mg-et-13-5-mg-comprime
2021
false
false
false
France
French
package leaflet
summary of product characteristics
guidelines for drug use
administration, oral
morpholines
morpholines
pyrimidines
pyrimidines
pyrroles
pyrroles
pemigatinib
cholangiocarcinoma
adult
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
cholangiocarcinoma
receptor, fibroblast growth factor, type 2
gene rearrangement
gene fusion
recurrence
Recurrent Cholangiocarcinoma
Refractory Cholangiocarcinoma
receptor, fibroblast growth factor, type 2
FGFR Inhibitor
Tyrosine Kinase Inhibitors
pemigatinib
pemigatinib

---
https://www.has-sante.fr/jcms/p_3287335/fr/pemazyre-pemigatinib
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
pemigatinib
protein kinase inhibitors
receptor, fibroblast growth factor, type 2
cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
FGFR2 Gene Fusion Positive
FGFR2 Gene Rearrangement
FGFR Inhibitor
evaluation of the transparency committee
pemigatinib

---
https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
pemigatinib
orphan drug production
administration, oral
receptors, fibroblast growth factor
FGFR Inhibitor
FGFR Inhibitor
adult
antineoplastic agents
antineoplastic agents
cholangiocarcinoma
receptor, fibroblast growth factor, type 2
product surveillance, postmarketing
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
Refractory Cholangiocarcinoma
cholangiocarcinoma
FGFR2 Gene Rearrangement
FGFR2 Gene Fusion Positive
drug interactions
pregnancy
breast feeding
protein kinase inhibitors
protein kinase inhibitors
drug evaluation, preclinical
pemigatinib
pemigatinib

---
Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.